Last $60.29 USD
Change Today +0.77 / 1.29%
Volume 10.4M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 6:40 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$59.34
Previous Close
$59.52
Day High
$60.41
Day Low
$59.34
52 Week High
10/24/14 - $60.41
52 Week Low
04/11/14 - $45.50
Market Cap
96.1B
Average Volume 10 Days
32.5M
EPS TTM
$2.94
Shares Outstanding
1.6B
EX-Date
01/13/15
P/E TM
20.5x
Dividend
$1.96
Dividend Yield
2.75%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 08/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

Abbvie Inc. Declares Quarterly Cash Dividend, Payable on February 13, 2015

AbbVie Inc. declared an increase in the company's quarterly cash dividend from $0.42 per share to $0.49 per share, payable on February 13, 2015 to stockholders of record as of January 15, 2015.

AbbVie Inc., Shire plc - M&A Call

To discuss the termination of proposed AbbVie Inc. and Shire plc transaction

Shire Is In Merger Talks With NPS

Shire plc (LSE:SHP) is considering another round of talks about a possible merger with NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP) after proposed merger of AbbVie Inc. (NYSE:ABBV) is cancelled. NPS Pharmaceuticals and Cubist Pharmaceuticals (CBST) are the two most likely merger partners for Shire plc, according to reports. Another would be merger partner is Allergan Inc. (NYSE:AGN), with the Paulson & Co. hedge fund voicing support for a deal, according to the Wall Street Journal. Allergan Inc. (NYSE:AGN) is also being pursued by Valeant Pharmaceuticals International, Inc. (TSX:VRX), but has so far rejected its entreaties. NPSP were up about 8.5% at $28.38, SHP about 3.2% at $184.93. CBST shares were up about 1.8% at $67.13.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $60.29 USD +0.77

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $147.26 USD +0.01
AstraZeneca PLC 4,328 GBp -7.00
Bristol-Myers Squibb Co $53.63 USD +1.13
Eli Lilly & Co $66.05 USD +1.70
Novo Nordisk A/S kr267.10 DKK -2.40
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 23.1x
Price/Sales 4.9x
Price/Book 18.2x
Price/Cash Flow 22.7x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.